• Active, not recruiting

NCT03110562 : Phase 3 - Bortezomib, Selinexor, and Dexamethasone in Patients With Myeloma (BOSTON)

Updated: Sep 22

BOSTON Study

Boston Study Selinexor

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade®) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes selinexor (i.e., SVdX or SdX) will be allowed at the point of IRC-confirmed objective disease progression per the IMWG criteria for patients in the Vd Arm.


Sponsor

Karyopharm Therapeutics Inc


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT03110562

Official Title: A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

First Posted: April 12, 2017

Click here for details on ClinicalTrials.gov

 

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information


Selinexor : National Cancer Institute

Selinexor : MedlinePlus Drug Information

 

Drug: Selinexor

Drug: Bortezomib

Drug: Dexamethasone

 

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Lancet; Nov. 2020

https://pubmed.ncbi.nlm.nih.gov/33189178/


Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Am J Hematol; June 2021

https://pubmed.ncbi.nlm.nih.gov/34062004/

 

457 Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Program: Oral and Poster Abstracts

Type: Oral

Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine

Hematology Disease Topics & Pathways:

Translational Research

Sunday, December 12, 2021: 12:00 PM


Learn more

 

NEWTON, Mass., Nov. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI)

Total of 17 Abstracts Selected for Presentation at the Meeting, Including Five Oral Presentations

Press release ASH 2021


Title: Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Presenter: Paula Restrepo, Icahn School of Medicine at Mount Sinai

Abstract #: 457

Session Type: Oral Presentation

Session: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine

Date and Time: Sunday, December 12, 2021 at 12:00 p.m. ET

Learn more:

Paper: Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature (confex.com)

 

Locations

United States, Florida

United States, Georgia

United States, Hawaii

United States, Iowa

United States, Kansas

United States, Kentucky

United States, Maryland

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Oklahoma

United States, Oregon

United States, South Carolina

United States, South Dakota

United States, Texas

Canada, Alberta

Canada, British Columbia

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec

Canada, Saskatchewan

Australia, New South Wales

Australia, Queensland

Australia, South Australia

Australia, Victoria

Europe

United Kingdom

Austria

Belgium

Bulgaria

Czechia

France

Germany

Greece

Hungary

Italy

Poland

Romania

Serbia

Spain

Ukraine

Asia

India

Israel

Russian Federation




Posts Archive